复发鼻咽癌碳离子放疗从LEM到MKM的RBE加权剂量转换
本研究基于20例复发鼻咽癌碳离子放疗患者数据,建立局部效应模型(LEM)与微剂量动力学模型(MKM)间RBE加权剂量转换曲线,并转换脑干、脊髓、视神经的LEM剂量约束。结果显示CTV1处方3.00 Gy(RBE)时转换因子为1.37(95%CI 1.35-1.39),CTV2处方2.70 Gy(RBE)时为1.46(95%CI 1.41-1.51),该曲线可为再程放疗提供剂量参考。
要点
- 20例复发鼻咽癌碳离子放疗数据建立LEM与MKM间RBE加权剂量转换曲线。
- CTV1 3.00 Gy(RBE)和CTV2 2.70 Gy(RBE)的转换因子分别为1.37和1.46。
- LEM 30 Gy(RBE)和45 Gy(RBE)(21分次)转换为MKM 16.64 Gy和30.72 Gy(16分次)。
核心结论
- 该转换曲线可将复发鼻咽癌碳离子放疗的LEM RBE加权剂量转换为MKM RBE加权剂量,为再程放疗提供剂量参考。
研究设计与样本
- 收集20例在本院接受碳离子放疗的复发鼻咽癌患者数据,用Raystation(V8A)以LEM生成治疗计划,再以MKM重算物理剂量生成MKM计划,采用等体积剂量法获得系列转换因子。
主要发现
- LEM计划中CTV1分次RBE加权剂量3.00 Gy(RBE)和CTV2 2.70 Gy(RBE)的转换因子分别为1.37(95%CI 1.35-1.39)和1.46(95%CI 1.41-1.51)。
- 对应LEM分次剂量从2.86 Gy(RBE)至0.24 Gy(RBE),平均转换因子从1.37(95%CI 1.33-1.41)至3.09(95%CI 2.94-3.24),涵盖OAR约束剂量。
- 21分次下LEM RBE加权剂量30 Gy(RBE)和45 Gy(RBE)转换为16分次下MKM RBE加权剂量16.64 Gy(RBE)和30.72 Gy(RBE)。
关键数值与推荐
- 脑干最大剂量<45 Gy(RBE),脊髓最大剂量<30 Gy(RBE)。
- 视神经/视交叉D20<30 Gy(RBE)。
临床怎么用
- 利用转换曲线将LEM计划的处方和OAR剂量约束转换为MKM对应值,为复发鼻咽癌再程碳离子放疗提供剂量参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to establish a conversion curve to convert the RBE-weighted doses calculated by local effect model I (LEM) (LEM RBE-weighted doses) in patients with locally recurrent nasopharyngeal carcinoma (rNPC) to the RBE-weighted doses calculated by microdosimetric kinetic model (MKM) (MKM RBE-weighted doses). We also converted the LEM dose constraints (RBE-weighted dose constraints in LEM plans) for the brain stem, spinal cord, and optic nerve based on this curve. METHODS: Data from 20 patients with rNPC receiving carbon-ion radiotherapy (CIRT) in our hospital were collected. LEM in Raystation (V8A, Raystation, Sweden) was used to generate treatment plans. The clinical target volume CTV1 (GTV + 5 mm) was given 3 Gy (RBE) per fraction. Ninety-nine percent of target volumes should be covered by 95% of the prescriptions; the maximum doses of the brainstem and spinal cord were < 45 Gy (RBE) and < 30 Gy (RBE), respectively. The doses covering 20% volumes of optical nerves/chiasms D20 were < 30 Gy (RBE). Then physical doses of the LEM plans were recalculated by using MKM in Raystation to generate MKM plans. A series of conversion factors (i.e., the ratio of LEM RBE-weighted dose to MKM RBE-weighted dose) was then obtained by using an isovolumetric dose method. The LEM plan prescriptions (LEM prescription) and dose constraints of the organs at risk (OARs) (OAR constraints) were converted to the corresponding MKM prescriptions and dose constraints using this conversion curve. RESULTS: For the CTV1 fractional RBE-weighted dose prescription of 3.00 Gy (RBE) and CTV2 of 2.70 Gy (RBE) in LEM plans, the conversion factors (LEM RBE-weighted dose/MKM RBE-weighted dose) were 1.37 (CI 95% 1.35-1.39) and 1.46 (1.41-1.51), respectively. The average conversion factors from 1.37 (CI 95% 1.33-1.41) to 3.09 (2.94-3.24) corresponded to the LEM fractionated doses from 2.86 Gy (RBE) to 0.24 Gy (RBE), including the doses constraining upon OARs. LEM RBE-weighted doses of 30 Gy (RBE) and 45 Gy (RBE) in 21 fractions were converted to MKM RBE-weighted doses of 16.64 Gy (RBE) and 30.72 Gy (RBE) in 16 fractions. CONCLUSIONS: This conversion curve could be used to convert LEM RBE-weighted doses to MKM RBE-weighted doses for patients with rNPC receiving CIRT, providing dose references for re-irradiation therapy.
引用
- Zhang L, Wang W, Hu J, et al. RBE-weighted dose conversions for patients with recurrent nasopharyngeal carcinoma receiving carbon-ion radiotherapy from the local effect model to the microdosimetric kinetic model. Radiat Oncol. 2020. PMID: 33302998. doi:10.1186/s13014-020-01723-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。